Log In
BCIQ
Print this Print this
 

CT340

  Manage Alerts
Collapse Summary General Information
Company Sienna Biopharmaceuticals Inc.
DescriptionTrkA, MAP2K3, and JAK3 kinase inhibitor
Molecular Target Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1) ; Mitogen-activated protein kinase kinase 3 (MAP2K3)
Mechanism of Action 
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today